Arin Tactical Tail Risk ETF ATTR 深 沪
等待开盘 12-18 09:30:00 美东时间
90.0767
-0.270
-0.30%
华盛通- 最 高90.1801
- 今 开90.18
- 成交量 3772股
- 最 低 90.0767
- 昨 收 90.3463
- 总市值 0
- 52周最高 90.5782
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 89.93
- 委 比 0.00%
- 总股本 --
- 历史最高 90.5782
- 量 比 1.68
- 振 幅 0.11%
- 历史最低 89.93
- 每 手 1
- 风险率 0.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alnylam Pharma To Invest $250M To Advance siRNA Enzymatic-Ligation Manufacturing Facility
New platform is expected to substantially increase manufacturing capacity and lower production costs, enabling investment in expanding pipelineFDA has accepted Alnylam's enzymatic ligation manufacturing platform into its
12-17 21:03
Natural Grocers® Launches New Organic Essential Oils
Customers can choose from 10 different scents for their next indulgent aromatic escape at the company's Always AffordableSM prices LAKEWOOD, Colo., Dec. 16, 2025 /PRNewswire/ -- Natural Groc...
12-17 04:49
Health Canada Approves Alnylam's AMVUTTRA For ATTR Cardiomyopathy
Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with wild-type or
12-16 21:11
Alnylam announces partial repurchase of convertible notes due 2027
Alnylam Pharmaceuticals (ALNY) said it reached privately negotiated agreements to repurchase for cash about $34.4M of its 1.00% Convertible Senior Notes due 2027. The company will pay roughly $51.9M i...
12-11 20:54
What's Going On With Alnylam Stock On Friday?
Alnylam stock climbs as earnings beat, sales soar and new Amvuttra data shows cardiac benefits, adding momentum to its strong 2025 run.
11-29 01:42
诺和诺德股价暴涨 公司连发重磅消息 退出竞购获华尔街支持
①诺和诺德旗下实验性药物coramitug的Ⅱ期临床试验数据公布，前一天还发布司美格鲁肽对代谢相关脂肪性肝炎疗效的数据； ②上周末，诺和诺德退出竞购Metsera公司，市场解读为战略决策，旨在保持现金流和长期增长前景。
11-12 04:26
诺和诺德连发重磅消息：退出Metsera竞购、司美格鲁肽降低肝损伤、印度市场降价37%
①诺和诺德旗下实验性药物coramitug的Ⅱ期临床试验数据公布，前一天还发布司美格鲁肽对代谢相关脂肪性肝炎疗效的数据；②上周末，诺和诺德退出竞购Metser...
11-12 04:26
Reported Saturday, Alnylam Pharmaceuticals HELIOS-B Phase 3 Study Of AMVUTTRA Shows Vutrisiran Improved Cardiac Structure And Function In ATTR-CM Patients With Amyloid Regression And Preserved Kidney Function
− Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran's Differentiated Profile –− Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate that
11-10 16:58
URBAN ONE, INC. REPORTS THIRD QUARTER 2025 RESULTS
SILVER SPRING, Md., Nov. 4, 2025 /PRNewswire/ -- Urban One, Inc. (NASDAQ: UONEK and UONE) today reported its results for the three months ended September 30, 2025. For the three months ended...
11-04 20:00
Simon® Reports Third Quarter 2025 Results
Increases Full Year 2025 Real Estate FFO per share guidance Raises quarterly dividend by 4.8% year-over-year to $2.20 per share Completes acquisition of remaining 12% interest in The Taubman...
11-04 05:05
